Defining Fractional Inhibitory Concentration Index Cutoffs for Additive Interactions Based on Self-Drug Additive Combinations, Monte Carlo Simulation Analysis, and In Vitro - In Vivo Correlation Data for Antifungal Drug Combinations against Aspergillus fumigatus
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The fractional inhibitory concentration (FIC) index range of 0.5 to 4 that is commonly used to define additivity results in no interactions in most combination studies of antifungal agents. These results may differ from those of in vivo studies, where positive and negative interactions may be observed. We reassessed this in vitro FIC index range based on (i) the experimental variation of the checkerboard technique using multiple replicates, (ii) the ability to correctly determine purely additive self-drug and two-drug antagonistic combinations of amphotericin B (AMB) and voriconazole (VRC), (iii) Monte Carlo simulation analysis, and (iv) in vitro - in vivo correlation using experimental models of invasive pulmonary aspergillosis against the same Aspergillus fumigatus isolate based on visual, spectrophotometric, and colorimetric determinations of FICs after 24 and 48 h of incubation. FICs obtained after 24 h of incubation ranged from 0.5 to 1.25 for the self-drug additive combinations of AMB plus AMB and VRC plus VRC and from 2.25 to 4.25 for the antagonistic combination of AMB plus VRC. Monte Carlo simulation analysis showed that self-drug combinations were correctly classified as additive and that the combination of AMB plus VRC was correctly classified as antagonistic for >85% of the simulated FICs when deviation of the 95% confidence interval (CI) of replicate FICs from the additivity range of 1 to 1.25 was used to assess interactions after 24 h. In vitro - in vivo correlation analysis showed that the 95% CIs of the FICs of the in vivo synergistic combination anidulafungin plus VRC determined after 24 h were lower than 1 and the 95% CIs of the FICs of the in vivo antagonistic combination AMB plus ravuconazole were higher than 1.25. Adequate insight into weak pharmacodynamic interactions with in vivo relevance may be obtained by demonstrating that triplicate FICs at 24 h are outside an inclusive additivity range of 1 to 1.25.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotics in Laboratory Medicine.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-4-653_4 · Cited by 2,779
Synergy, antagonism, and what the chequerboard puts between them
Odds, F. C. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg301 · Cited by 2,481
Rex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,573
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791
Combination Antifungal Therapy for Invasive Aspergillosis
Marr, K. A., Boeckh, M., Carter, R. A., Kim, H. W., & Corey, L. (2004) · Clinical Infectious Diseases · doi:10.1086/423380 · Cited by 596
Combination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541 · cited 2×
“5 and 4 were suggested for defining additivity/indifference (1, 12, 22).”
BackgroundThe fractional inhibitory concentration (FIC) index as a measure of synergy
Hall, M. J., Middleton, R. F., & Westmacott, D. (1983) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/11.5.427 · Cited by 348
Kirkpatrick, W. R., Perea, S., Coco, B. J., & Patterson, T. F. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2564-2568.2002 · Cited by 282
Perea, S., Gonzalez, G., Fothergill, A. W., Kirkpatrick, W. R., Rinaldi, M. G., & Patterson, T. F. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.3039-3041.2002 · Cited by 186
Colorimetric Assay for Antifungal Susceptibility Testing of Aspergillus Species
Meletiadis, J., Mouton, J. W., Meis, J. F. G. M., Bouman, B. A., Donnelly, J. P., Verweij, P. E., & EUROFUNG Network (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3402-3408.2001 · Cited by 161
Self-citationClemons, K. V., Espiritu, M., Parmar, R., & Stevens, D. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.4867-4875.2005 · Cited by 149
Meletiadis, J., Verweij, P. E., Te Dorsthorst, D. T. A., Meis, J. F. G. M., & Mouton, J. W. (2005) · Medical Mycology · doi:10.1080/13693780410001731547 · Cited by 110
Self-citationMeletiadis, J., Mouton, J. W., Rodriguez-Tudela, J. L., Meis, J. F. G. M., & Verweij, P. E. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.470-472.2000 · Cited by 110
Self-citationMeletiadis, J., Petraitis, V., Petraitiene, R., Lin, P., Stergiopoulou, T., Kelaher, A. M., Sein, T., Schaufele, R. L., Bacher, J., & Walsh, T. J. (2006) · The Journal of Infectious Diseases · doi:10.1086/506617 · Cited by 108
Self-citationPetraitis, V., Petraitiene, R., Hope, W. W., Meletiadis, J., Mickiene, D., Hughes, J. E., Cotton, M. P., Stergiopoulou, T., Kasai, M., Francesconi, A., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00329-09 · Cited by 94
Self-citationMeletiadis, J., Mouton, J. W., Meis, J. F. G. M., Bouman, B. A., Donnelly, P. J., Verweij, P. E., & EUROFUNG Network (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.12.4256-4263.2001 · Cited by 77
Self-citationAntifungal chemotherapy: advances and perspectives
Groll, A., & Walsh, T. (2002) · Swiss Medical Weekly · doi:10.4414/smw.2002.09729 · Cited by 76
Self-citationEfficacy of Caspofungin and Voriconazole Combinations in Experimental Aspergillosis
MacCallum, D. M., Whyte, J. A., & Odds, F. C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3697-3701.2005 · Cited by 73
Cuenca-Estrella, M., Gomez-Lopez, A., Garcia-Effron, G., Alcazar-Fuoli, L., Mellado, E., Buitrago, M. J., & Rodriguez-Tudela, J. L. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.1232-1235.2005 · Cited by 72
Sionov, E., Mendlovic, S., & Segal, E. (2005) · Journal of Infection · doi:10.1016/j.jinf.2005.10.015 · Cited by 47
Correlations between Methods for Measurement of Synergy
Berenbaum, M. C. (1980) · The Journal of Infectious Diseases · doi:10.1093/infdis/142.3.476 · Cited by 46
Spontaneous bilateral bacterial empyema in a patient with nephrotic syndrome
Chen, W., Huang, J., Chen, K., Hsueh, P., & Yang, P. (2006) · Journal of Infection · doi:10.1016/j.jinf.2005.12.003 · Cited by 33
Meletiadis, J., Dorsthorst, D. T. A. T., & Verweij, P. E. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.07.011 · Cited by 30
Self-citation
Cited by
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Coates, A. R. M., Hu, Y., Holt, J., & Yeh, P. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1705155 · Cited by 227
“Synergy is measured in vitro using the Fractional Inhibitory Concentration Index (FICI) [39,40], which is the standard for assessing synergy, indifference or antagonism between two antibiotics [35,39].”
BackgroundInfluentialStructural Basis of Mycobacterium tuberculosis Transcription and Transcription Inhibition
Lin, W., Mandal, S., Degen, D., Liu, Y., Ebright, Y. W., Li, S., Feng, Y., Zhang, Y., Mandal, S., Jiang, Y., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.03.001 · Cited by 178
Unraveling the Biology of a Fungal Meningitis Pathogen Using Chemical Genetics
Brown, J. C. S., Nelson, J., VanderSluis, B., Deshpande, R., Butts, A., Kagan, S., Polacheck, I., Krysan, D. J., Myers, C. L., & Madhani, H. D. (2014) · Cell · doi:10.1016/j.cell.2014.10.044 · Cited by 84
“We determined FICI using a standard checkerboard assay (Hsieh et al., 1993), calculating FICI as described using a 50% growth inhibition cutoff for MICs for individual compounds (Hsieh et al., 1993; Meletiadis et al., 2010), then using a standard cutoff of FICI < 0.5 to define synergy.”
InfluentialWambaugh, M. A., Shakya, V. P. S., Lewis, A. J., Mulvey, M. A., & Brown, J. C. S. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2001644 · Cited by 63
Metadata
- Authors
- Meletiadis, J., Pournaras, S., Roilides, E., & Walsh, T. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2010-02
- Volume
- 54
- Issue
- 2
- Pages
- 602-609
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2138023605
- Cited by
- 325
- References
- 25
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.